Published in Clin Vaccine Immunol on November 03, 2010
Applications of nanotechnology for immunology. Nat Rev Immunol (2013) 1.65
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. Oncoimmunology (2014) 1.28
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09
Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99
Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer (2013) 0.95
Nanoscale assemblies and their biomedical applications. J R Soc Interface (2013) 0.94
Improving T cell responses to modified peptides in tumor vaccines. Immunol Res (2013) 0.90
Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother (2014) 0.89
Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. Immunotherapy (2014) 0.87
Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications. Viruses (2015) 0.87
DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother (2014) 0.87
Vaccination strategies for neuro-oncology. Neuro Oncol (2015) 0.85
Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology (2015) 0.83
Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients. Oncoimmunology (2015) 0.81
Carbohydrate-based cancer vaccines: target cancer with sugar bullets. Glycoconj J (2012) 0.80
Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release (2016) 0.80
Functional characterization of biodegradable nanoparticles as antigen delivery system. J Exp Clin Cancer Res (2015) 0.80
Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy. Small (2015) 0.80
A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors. J Immunother (2015) 0.78
Enhanced Control of Bladder-Associated Tumors Using Shrimp Anti-Lipopolysaccharide Factor (SALF) Antimicrobial Peptide as a Cancer Vaccine Adjuvant in Mice. Mar Drugs (2015) 0.78
Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system. Int J Mol Sci (2015) 0.78
Anti-cancer vaccines - a one-hit wonder? Yale J Biol Med (2014) 0.76
Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders. PLoS Pathog (2014) 0.76
Immunogenicity and safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice and dogs. Oncotarget (2016) 0.76
Active and passive immunization for cancer. Hum Vaccin Immunother (2014) 0.76
PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors. Cancer Immunol Res (2016) 0.75
The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. Int J Mol Sci (2017) 0.75
Systems Biology Approach for Cancer Vaccine Development and Evaluation. Vaccines (Basel) (2015) 0.75
Enhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic' CpG functionalization of poly-lactic-co-glycolic acid nanoparticles. Nanomedicine (Lond) (2015) 0.75
Current status of autologous breast tumor cell-based vaccines. Expert Rev Vaccines (2014) 0.75
Immunogenic FEAT protein circulates in the bloodstream of cancer patients. J Transl Med (2016) 0.75
Human dendritic cell activation induced by a permannosylated dendron containing an antigenic GM3-lactone mimetic. Beilstein J Org Chem (2014) 0.75
Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer. Hum Vaccin Immunother (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Cancer genes and the pathways they control. Nat Med (2004) 24.22
The cancer genome. Nature (2009) 23.13
The heat-shock proteins. Annu Rev Genet (1988) 22.28
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 13.03
T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature (1998) 11.08
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20
Progress in human tumour immunology and immunotherapy. Nature (2001) 6.97
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 6.60
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 6.36
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res (2001) 5.48
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov (2006) 5.19
Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol (2005) 5.09
The concept of immunological surveillance. Prog Exp Tumor Res (1970) 4.76
A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer (1976) 4.76
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med (1998) 4.65
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med (1994) 3.94
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol (1999) 3.76
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Automated network analysis identifies core pathways in glioblastoma. PLoS One (2010) 3.64
Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res (2003) 3.44
T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 3.39
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta (1999) 3.17
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11
The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol (2003) 3.06
alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res (2004) 3.00
Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A (1986) 2.94
A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med (1992) 2.92
Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (1997) 2.92
Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics (1994) 2.88
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A (2008) 2.73
Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med (1996) 2.69
IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol (1997) 2.67
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol (2002) 2.54
Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst (1995) 2.47
Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res (2003) 2.45
Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol (2001) 2.42
CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer (2003) 2.37
Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol (2009) 2.33
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med (1996) 2.31
Cancer; a biological approach. I. The processes of control. Br Med J (1957) 2.29
Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. J Immunol (2005) 2.27
A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother (2004) 2.16
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood (2008) 2.13
Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity (2000) 2.13
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest (2001) 2.11
Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06
The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity (1999) 2.06
Control of immune homeostasis by naturally arising regulatory CD4+ T cells. Curr Opin Immunol (2003) 2.04
Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood (2001) 2.01
Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol (1994) 1.98
Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci (2009) 1.96
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene (2008) 1.94
In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst (1997) 1.92
Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A (2009) 1.92
Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med (2000) 1.90
Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J Immunol (1994) 1.87
Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer (2007) 1.85
Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res (2003) 1.83
Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol (1998) 1.82
Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother (2006) 1.75
Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol (2003) 1.74
Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J (1957) 1.74
Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood (2007) 1.72
Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res (1998) 1.72
Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A (1996) 1.72
The makings of a tumor rejection antigen. Immunity (1999) 1.71
Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 1.71
GM-CSF-based cancer vaccines. Immunol Rev (2002) 1.71
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66
Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med (2000) 1.62
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst (2002) 1.56
Cancer genome sequencing--an interim analysis. Cancer Res (2009) 1.52
Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res (2002) 1.52
Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer (2009) 3.33
Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics (2013) 1.24
Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization. Infect Agent Cancer (2012) 1.17
Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J Med Virol (2004) 1.13
Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis. PLoS One (2013) 1.06
Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies. Oncology (2015) 1.03
Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population. J Med Virol (2006) 1.02
Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005. J Exp Clin Cancer Res (2009) 1.02
Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy. Cancer Epidemiol Biomarkers Prev (2010) 1.00
Human papillomavirus genotypes and HPV16 variants in penile carcinoma. Int J Cancer (2008) 0.99
Effects of adjuvants on IgG subclasses elicited by virus-like particles. J Transl Med (2012) 0.99
Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. J Transl Med (2005) 0.98
Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review. Gynecol Oncol (2012) 0.97
Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol (2013) 0.95
Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. J Transl Med (2009) 0.95
Virus-like particles as particulate vaccines. Curr HIV Res (2010) 0.94
Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy. Infect Agent Cancer (2007) 0.92
Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco. Transgenic Res (2008) 0.92
Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bioinformatics (2008) 0.92
Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines (2009) 0.91
Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev Vaccines (2011) 0.91
Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother (2014) 0.89
Screening of HIV-1 isolates by reverse heteroduplex mobility assay and identification of non-B subtypes in Italy. J Acquir Immune Defic Syndr (2004) 0.89
Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer (2008) 0.89
Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi's sarcoma lesions during pre-AIDS and AIDS era. Virology (2010) 0.89
Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons? Immunotherapy (2011) 0.87
Kaposi's sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies. Clin Dermatol (2013) 0.87
TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer (2011) 0.87
Cardiac tamponade and heart failure due to myopericarditis as a presentation of infection with the pandemic H1N1 2009 influenza A virus. J Clin Microbiol (2010) 0.87
Systems biology applied to vaccine and immunotherapy development. BMC Syst Biol (2011) 0.85
High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts. Planta (2009) 0.84
New adjuvants in evolving vaccine strategies. Expert Opin Biol Ther (2011) 0.83
Molecular immune signatures of HIV-1 vaccines in human PBMCs. FEBS Lett (2009) 0.83
VLPs and particle strategies for cancer vaccines. Expert Rev Vaccines (2013) 0.83
MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients. Biomarkers (2010) 0.82
Somatic mutations of STK11 gene in human papillomavirus positive and negative penile cancer. Infect Agent Cancer (2013) 0.82
TP53 codon 72 polymorphism in classic, endemic and epidemic Kaposi's sarcoma in African and Caucasian patients. Oncology (2009) 0.82
Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. J Transl Med (2010) 0.82
Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example. Retrovirology (2007) 0.82
Functional interaction between human papillomavirus type 16 E6 and E7 oncoproteins and cigarette smoke components in lung epithelial cells. PLoS One (2012) 0.82
Infectious agents and human malignancies. Front Biosci (Landmark Ed) (2009) 0.82
TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix. J Transl Med (2014) 0.82
Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy. Infect Agent Cancer (2008) 0.81
Molecular epidemiology of human herpesvirus 8 variants in Kaposi's sarcoma from Iranian patients. Virus Res (2011) 0.81
TP53 codon 72 polymorphism and risk of conjunctival squamous cell carcinoma in Uganda. Cancer Detect Prev (2005) 0.81
Characterization of the human papillomavirus (HPV) integration sites into genital cancers. Pathol Oncol Res (2012) 0.81
Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration. Clin Vaccine Immunol (2012) 0.81
Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. Cancer Immunol Immunother (2015) 0.80
Evaluation of a modified version of Heteroduplex Mobility Assay for rapid screening of HIV-1 isolates in epidemics characterized by mono/dual clade predominance. J Virol Methods (2005) 0.80
High prevalence of human papillomavirus infection in Eastern European and West African women immigrants in South Italy. APMIS (2011) 0.80
Innate immunity and hepatitis C virus infection: a microarray's view. Infect Agent Cancer (2012) 0.80
An overview of new biomolecular pathways in pathogen-related cancers. Future Oncol (2015) 0.79
HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies. Infect Agent Cancer (2012) 0.79
Infections and cancer: debate about using vaccines as a cancer control tool. Infect Agent Cancer (2013) 0.78
Developments in virus-like particle-based vaccines for HIV. Expert Rev Vaccines (2013) 0.78
Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate. J Transl Med (2013) 0.78
Cellular prognostic markers in hepatocellular carcinoma. Future Oncol (2015) 0.78
Formation of self-assembled triple-layered rotavirus-like particles (tlRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines. J Med Virol (2014) 0.78
Molecular characterization analysis of the outer protein layer (VP7) from human rotavirus A genotype G1 isolate identified in Iran: implications for vaccine development. New Microbiol (2012) 0.77
Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches. Expert Rev Vaccines (2010) 0.77
Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach. J Transl Med (2014) 0.77
Evolution of the HIV-1 V3 region in the Italian epidemic. New Microbiol (2007) 0.77